The molecular pathogenesis of acute myeloid leukemia
- PMID: 16236521
- DOI: 10.1016/j.critrevonc.2004.10.012
The molecular pathogenesis of acute myeloid leukemia
Abstract
The description of the molecular pathogenesis of acute myeloid leukemias (AML) has seen dramatic progress over the last years. Two major types of genetic events have been described that are crucial for leukemic transformation: alterations in myeloid transcription factors governing hematopoietic differentiation and activating mutations of signal transduction intermediates. These processes are highly interdependent, since the molecular events changing the transcriptional control in hematopoietic progenitor cells modify the composition of signal transduction molecules available for growth factor receptors, while the activating mutations in signal transduction molecules induce alterations in the activity and expression of several transcription factors that are crucial for normal myeloid differentiation. The purpose of this article is to review the current literature describing these genetic events, their biological consequences and their clinical implications. As the article will show, the recent description of several critical transforming mutations in AML may soon give rise to more efficient and less toxic molecularly targeted therapies of this deadly disease.
Similar articles
-
Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16. doi: 10.1016/j.exphem.2007.01.018. Exp Hematol. 2007. PMID: 17379095
-
Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.J Cell Physiol. 2009 Jul;220(1):16-20. doi: 10.1002/jcp.21769. J Cell Physiol. 2009. PMID: 19334039 Review.
-
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.Crit Rev Oncol Hematol. 2007 Sep;63(3):215-30. doi: 10.1016/j.critrevonc.2007.05.005. Epub 2007 Jul 19. Crit Rev Oncol Hematol. 2007. PMID: 17658267 Review.
-
Lineage-specific transcription factor aberrations in AML.Cancer Treat Res. 2010;145:109-25. doi: 10.1007/978-0-387-69259-3_7. Cancer Treat Res. 2010. PMID: 20306248 Review.
-
[Pathobiology of acute myeloid leukemia].Med Klin (Munich). 2007 Apr 15;102(4):290-5. doi: 10.1007/s00063-007-1035-2. Med Klin (Munich). 2007. PMID: 17426932 Review. German.
Cited by
-
The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins.Exp Ther Med. 2013 Aug;6(2):299-304. doi: 10.3892/etm.2013.1161. Epub 2013 Jun 14. Exp Ther Med. 2013. PMID: 24137178 Free PMC article.
-
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20. Haematologica. 2011. PMID: 21933861 Free PMC article. Clinical Trial.
-
Acute myeloid leukaemia.Lancet. 2018 Aug 18;392(10147):593-606. doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2. Lancet. 2018. PMID: 30078459 Free PMC article. Review.
-
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. Epub 2014 Oct 17. Leukemia. 2015. PMID: 25322685
-
High constitutive Akt2 activity in U937 promonocytes: effective reduction of Akt2 phosphorylation by the histamine H2-receptor and the β2-adrenergic receptor.Naunyn Schmiedebergs Arch Pharmacol. 2016 Jan;389(1):87-101. doi: 10.1007/s00210-015-1179-1. Epub 2015 Oct 16. Naunyn Schmiedebergs Arch Pharmacol. 2016. PMID: 26475619
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials